family with sequence similarity 230 member BGenealiases: []
Q-omics provides the consensus-scored FAM230B profile across patient tissues and cancer cell-line models. FAM230B expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, FAM230B is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, FAM230B RNA expression shows 6,033 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, THCA, and STAD as cancer lineages where FAM230B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM230B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM230B survival associations across molecular data types. FAM230B RNA expression shows survival associations in the most cancer types (12), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM230B RNA expression–survival associations across cancer types. High FAM230B expression shows unfavorable associations in UCEC, ACC and KICH, but favorable associations in PAAD, THCA and ESCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for FAM230B RNA expression.
This table summarizes FAM230B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM230B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM230B shows higher tumor expression in THCA and UCEC. The THCA box plot shows higher FAM230B RNA expression in tumor versus normal tissue (log2 FC = +0.095, t-test p < 0.001).
This table shows molecular features associated with FAM230B in patient tissues and cancer cell lines. In patient samples, FAM230B shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
